Wick Capital Partners LLC Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Wick Capital Partners LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 14,364.5% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 56,267 shares of the company’s stock after purchasing an additional 55,878 shares during the quarter. Eli Lilly and Company comprises 7.4% of Wick Capital Partners LLC’s portfolio, making the stock its 4th biggest holding. Wick Capital Partners LLC’s holdings in Eli Lilly and Company were worth $43,438,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Principal Financial Group Inc. boosted its holdings in shares of Eli Lilly and Company by 5.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock valued at $1,070,698,000 after acquiring an additional 60,306 shares during the last quarter. Invst LLC increased its holdings in Eli Lilly and Company by 3.5% in the third quarter. Invst LLC now owns 5,552 shares of the company’s stock valued at $4,918,000 after buying an additional 189 shares in the last quarter. McIlrath & Eck LLC increased its stake in shares of Eli Lilly and Company by 3.4% in the 3rd quarter. McIlrath & Eck LLC now owns 481 shares of the company’s stock valued at $426,000 after purchasing an additional 16 shares in the last quarter. Virtu Financial LLC raised its holdings in Eli Lilly and Company by 111.7% in the 3rd quarter. Virtu Financial LLC now owns 6,531 shares of the company’s stock worth $5,786,000 after purchasing an additional 3,446 shares during the period. Finally, SOA Wealth Advisors LLC. boosted its position in Eli Lilly and Company by 2.4% during the third quarter. SOA Wealth Advisors LLC. now owns 864 shares of the company’s stock worth $766,000 after purchasing an additional 20 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on LLY shares. Morgan Stanley reduced their price target on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a research report on Wednesday, April 9th. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. The Goldman Sachs Group raised Eli Lilly and Company from a “neutral” rating to a “buy” rating and lowered their price target for the stock from $892.00 to $888.00 in a research note on Tuesday, April 8th. Citigroup reduced their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, Hsbc Global Res cut shares of Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,000.32.

Eli Lilly and Company Stock Up 0.9 %

Shares of NYSE LLY opened at $885.54 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a fifty day moving average price of $828.13 and a 200 day moving average price of $817.35. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market cap of $839.64 billion, a P/E ratio of 75.62, a P/E/G ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.